Pulmonary Hypertension Spotlight-Pulmonary Arterial Hypertension:Therapeutic Dilemmas

Video Transcription

Video Summary

The session on "Therapeutic Dilemmas in Pulmonary Arterial Hypertension" discussed the use of upfront therapies for severe PAH and the importance of risk assessment in therapy decision-making. A case was presented of a 55-year-old female with methamphetamine-induced pulmonary hypertension who was admitted to the ICU with severe symptoms. Various risk assessment tools and registries were discussed, highlighting the need to calculate risk formally rather than relying on subjective assessment. The World Symposium guidelines and ESC-ERS guidelines were mentioned, which recommend initial combination therapy for high-risk patients and monotherapy for low-risk patients. For intermediate-risk patients, a nuanced approach is recommended. The benefits and risks of combination therapy were discussed, along with the available FDA-approved therapies. The importance of achieving and maintaining low-risk status was emphasized, and the case of the patient in the study was used to illustrate the need for aggressive therapy in severe PAH. Transitioning between different therapies, such as parenteral to inhaled or periprostaticinoids to non-prostaticinoids, was also discussed, highlighting the need for careful monitoring and expert guidance.

Meta Tag

Category Pulmonary Vascular Disease

Speaker Ronald Oudiz, MD

Speaker Paresh Giri, MD, FCCP

Speaker Jean Elwing, MD, FCCP

Keywords

Pulmonary Arterial Hypertension

Upfront Therapies

Risk Assessment

Combination Therapy

Low-risk Status

FDA-approved Therapies

Severe Symptoms

Expert Guidance